Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

The Global Non-melanoma Skin Cancer (NMSC) Market (2018-2022) by Type of NMSC, Therapy and Region - ResearchAndMarkets.com

Research and Markets
Posted on: 09 Jan 19

The "Global Non-melanoma Skin Cancer Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The non-melanoma skin cancer market will register a CAGR of almost 6% by 2022.

The latest trend gaining momentum in the market is the high off-label use of topical treatments for NMSC.

According to the report, one of the major drivers for this market is the rising incidence of NMSC across the globe, especially in Europe, the US, and Australia.

Further, the report states that one of the major factors hindering the growth of this market is the low data availability on NMSC statistics in cancer registries.

Key Players

  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • 3M Pharmaceuticals

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY TYPE OF NMSC

  • Segmentation by type of NMSC
  • Comparison by type of NMSC
  • BCC - Market size and forecast 2017-2022
  • SCC - Market size and forecast 2017-2022
  • Market opportunity by type of NMSC

PART 09: MARKET SEGMENTATION BY THERAPY

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical Segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

  • Increasing incidence of NMSC
  • Surgery considered as a first-line curative approach for NMSC
  • High off-label use of topical treatments for NMSC
  • Low physician adherence to NMSC diagnostic and treatment guidelines

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • 3M Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/wjv5vf/the_global?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005643/en/

Business Wire
www.businesswire.com

Last updated on: 09/01/2019

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.